- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06097767
the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy
Evaluation of the Incidence of Necrotizing Enterocolitis in Preterm Infants With Respiratory Distress Syndrome Undergoing Caffeine Therapy
It is a randomized, prospective study; it will be carried out in the NICU at Alzahraa University Hospital including 50 newborn babies diagnosed with respiratory distress syndrome.
The purpose of this study is to :
- Investigate the protective caffeine on necrotizing enterocolitis in respiratory distress syndrome preterm infants.
- Detect the impact of caffeine protocol treatment on the in-incidence of necrotizing enterocolitis in respiratory distress syndrome preterm infants in neonatal intensive care
1- Control group It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks.
2- Caffeine-treated group It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- NICU at Alzahraa University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All preterm infants with respiratory distress syndrome.
Exclusion Criteria:
- Preterm admitted to NICU for other reasons rather than respiratory distress
- Major congenital anomalies
- spontaneous intestinal perforation
- Endocrinal Dysfunctions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Control group
It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks receives regular intervention for RDS
|
it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
|
Active Comparator: Caffeine-treated group
It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
|
It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
decreasing NEC rates
Time Frame: 1 year
|
decreasing NEC rates and stage ≥2 and death.
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Gastrointestinal Diseases
- Infant, Newborn, Diseases
- Gastroenteritis
- Intestinal Diseases
- Infant, Premature, Diseases
- Enterocolitis
- Enterocolitis, Necrotizing
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Anti-Bacterial Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Caffeine
- Amikacin
- Caffeine citrate
Other Study ID Numbers
- RHDIRB2018122001/2116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacological Action of Drug
-
University of MalayaMinistry of Health, MalaysiaUnknownPharmacokinetics | Molecular Mechanisms of Pharmacological ActionMalaysia
-
Balance TherapeuticsCompletedMolecular Mechanisms of Pharmacological ActionUnited Kingdom
-
Universidad Nacional de SaltaFundacion Mundo SanoNot yet recruitingPharmacological Action
-
Federal State Budgetary Scientific Institution,...The League of Clinical Research, Russia; Institute of Biomedical Chemistry,...Completed
-
Masaryk Hospital Usti nad LabemUnknownPharmacological ActionCzechia
-
Ervin TasoUniversity of BelgradeCompletedPharmacological ActionSerbia
-
Tianjin Medical University General HospitalRecruiting
-
Qin ZhangRecruitingPharmacological ActionChina
-
Food and Nutrition Research Institute, PhilippinesAteneo de Manila University; De La Salle Medical and Health Sciences InstituteActive, not recruiting
-
Fudan UniversityShanghai First Maternity and Infant Hospital; Women and children's hospital...UnknownPharmacological ActionChina
Clinical Trials on Amikacin
-
University Medical Center GroningenRecruitingTuberculosisNetherlands
-
National Heart Institute, EgyptCompleted
-
Association Pour La Promotion A Tours De La Reanimation...UnknownVentilator Associated PneumoniaFrance
-
Cardeas PharmaCompletedHealthyUnited States
-
Insmed IncorporatedWithdrawn
-
Insmed IncorporatedCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedVentilator Associated PneumoniaFrance
-
Insmed IncorporatedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedMycobacterium Infections, NontuberculousUnited States, Canada
-
Pontificia Universidad Catolica de ChileCompleted
-
Centre Hospitalier Universitaire de NīmesCompleted